TDMS No. 20311 - 02 Test Type: CHRONIC Route: IN-UTERO P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

AZT/Drug Combinations Transplacental Carcinogenesis Study

CAS Number: AIDSTHERAPEU

Date Report Requested: 06/29/2009 Time Report Requested: 16:30:20 First Dose M/F: NA / 07/10/03

Lab: NCTR

C Number: C20311

**Lock Date:** 12/01/2008

Cage Range: ALL

Species/Strain: MICE/B6C3F1/NCTR

Date Range: ALL

Reasons For Removal: ALL

Removal Date Range: ALL

Treatment Groups: Include ALL

Study Gender: Female

**TDMSE Version:** 2.1.0

AZT/Drug Combinations Transplacental Carcinogenesis Study

CAS Number: AIDSTHERAPEU

Date Report Requested: 06/29/2009 Time Report Requested: 16:30:20 First Dose M/F: NA / 07/10/03

Lab: NCTR

C57BL/6N XC3H/HEN MTV-NCTR MICE FEMALE	AZT-H to 0	AZT-M to 0	AZT-L to 0	AZT-H/3TC-H to 0	AZT-M/3TC-M to 0	AZT-L/3TC-L to (
Disposition Summary						
Animals Initially in Study	48	47	48	48	51	48
Early Deaths Moribund Sacrifice	0	7	3	4	8	9
Natural Death	8 2	1	3	3	8 2	3
Survivors	2	'	O	0	_	O .
Moribund Sacrifice		3	2	1	2	2
Natural Death		1			1	
Terminal Sacrifice	37	28	38	35	35	32
Harvest Animals Examined Microscopically	1 48	7 47	2 47	5 48	3 51	2 48
Animais Examined microscopically	40	47	47	40	31	40
ALIMENTARY SYSTEM						
Esophagus	(47)	(47)	(46)	(48)	(50)	(47)
Gallbladder	(46)	(45)	(44)	(46)	(48)	(45)
Cyst		1 (2%)	2 (5%)			
Degeneration, Hyaline			4 (20()			4 (20/)
Infiltration Cellular, Lymphocyte Inflammation, Chronic		1 (2%)	1 (2%)			1 (2%)
Intestine Large, Cecum	(46)	(46)	(46)	(46)	(49)	(46)
Hyperplasia, Lymphoid	2 (4%)	(10)	2 (4%)	1 (2%)	2 (4%)	1 (2%)
Serosa, Hyperplasia	( /		(/	( /	( /	( /
Intestine Large, Colon	(46)	(46)	(46)	(46)	(50)	(46)
Intestine Large, Rectum	(46)	(46)	(46)	(46)	(50)	(46)
Hyperplasia, Lymphoid Intestine Small, Duodenum	(40)	(47)	(45)	1 (2%)	(40)	1 (2%)
Diverticulum	(46)	(47)	(45) 1 (2%)	(45)	(49)	(45)
Intestine Small, Ileum	(46)	(46)	(46)	(46)	(50)	(46)
Hyperplasia, Lymphoid	1 (2%)	(10)	2 (4%)	(13)	(55)	1 (2%)
Inflammation, Chronic Active	, ,		` '			, ,
Intestine Small, Jejunum	(46)	(45)	(46)	(46)	(48)	(46)
Hyperplasia, Lymphoid	1 (2%)		1 (2%)			
Epithelium, Hyperplasia Liver	(47)	(46)	(46)	(40)	(50)	(47)
Angiectasis	(47)	(46) 1 (2%)	(46)	(48)	(50) 1 (2%)	(47)
Autolysis		1 (278)			1 (270)	
Basophilic Focus	2 (4%)	2 (4%)	3 (7%)	7 (15%)	3 (6%)	2 (4%)
Basophilic Focus, Multiple	\ ·-/	( /	- (/	( /	1 (2%)	(/
Clear Cell Focus				1 (2%)	2 (4%)	
Congestion	1 (2%)				1 (2%)	
Cyst						

TDMS No. 20311 - 02 Test Type: CHRONIC

Species/Strain: MICE/B6C3F1/NCTR

a - Number of animals examined microscopically at site and number of animals with lesion

AZT/Drug Combinations Transplacental Carcinogenesis Study

CAS Number: AIDSTHERAPEU

Date Report Requested: 06/29/2009 Time Report Requested: 16:30:20 First Dose M/F: NA / 07/10/03

Lab: NCTR

(48)

(46)

(46)

C57BL/6N XC3H/HEN MTV-NCTR MICE FEMALE	AZT-H to 0	AZT-M to 0	AZT-L to 0	AZT-H/3TC-H to 0	AZT-M/3TC-M to 0	AZT-L/3TC-L to
Cyst Multilocular		1 (2%)				
Deformity						
Eosinophilic Focus	2 (4%)	1 (2%)		2 (4%)	1 (2%)	1 (2%)
Eosinophilic Focus, Multiple			1 (2%)			
Fatty Change						
Hematocyst		- 4			1 (2%)	
Hematopoietic Cell Proliferation	1 (2%)	2 (4%)			1 (2%)	
Hemorrhage	1 (2%)			( (50()		
Hepatodiaphragmatic Nodule				1 (2%)		
Infiltration Cellular, Histiocyte						
Infiltration Cellular, Lymphocyte	13 (28%)	13 (28%)	12 (26%)	13 (27%)	17 (34%)	10 (21%)
Inflammation, Chronic Active	2 (4%)	2 (4%)	3 (7%)	2 (4%)	2 (4%)	2 (4%)
Mineralization		- 4				
Mixed Cell Focus	- 4	2 (4%)	1 (2%)	1 (2%)	2 (4%)	2 (4%)
Necrosis	2 (4%)	5 (11%)		- 4	1 (2%)	1 (2%)
Tension Lipidosis	11 (23%)	2 (4%)	5 (11%)	6 (13%)	6 (12%)	8 (17%)
Vacuolization Cytoplasmic	18 (38%)	23 (50%)	19 (41%)	16 (33%)	28 (56%)	21 (45%)
Mesentery	(8)	(4)	(11)	(6)	(7)	(11)
Cyst			1 (9%)			
Hematocyst					1 (14%)	
Hemorrhage			2 (18%)	2 (33%)	1 (14%)	1 (9%)
Infiltration Cellular, Lymphocyte				1 (17%)	1 (14%)	
Fat, Necrosis	8 (100%)	3 (75%)	11 (100%)	5 (83%)	6 (86%)	9 (82%)
Pancreas	(46)	(46)	(46)	(48)	(49)	(46)
Cyst			1 (2%)			
Cytoplasmic Alteration	1 (2%)					
Edema			1 (2%)			
Infiltration Cellular, Lymphocyte	18 (39%)	15 (33%)	13 (28%)	18 (38%)	19 (39%)	16 (35%)
Inflammation, Chronic Active			1 (2%)			
Mineralization						
Necrosis			1 (2%)			
Acinus, Degeneration	1 (2%)	1 (2%)	2 (4%)		1 (2%)	1 (2%)
Duct, Dilatation						
Fat, Necrosis			1 (2%)			
Salivary Glands	(47)	(45)	(46)	(48)	(50)	(46)
Infiltration Cellular, Lymphocyte	38 (81%)	40 (89%)	39 (85%)	39 (81%)	46 (92%)	38 (83%)
Polyarteritis						
Acinus, Degeneration		1 (2%)		1 (2%)		
Stomach, Forestomach	(46)	(47)	(45)	(47)	(50)	(46)
Hyperkeratosis				2 (4%)		
Hyperplasia						
Inflammation, Chronic Active						
Keratin Cyst					1 (2%)	
Ulcer						
Epithelium, Hyperplasia		1 (2%)		1 (2%)		2 (4%)
Stomach Glandular	(46)	(46)	(45)	(46)	(48)	(46)

(46)

TDMS No. 20311 - 02 Test Type: CHRONIC

Species/Strain: MICE/B6C3F1/NCTR

Stomach, Glandular

Route: IN-UTERO

(45)

(46)

a - Number of animals examined microscopically at site and number of animals with lesion

AZT/Drug Combinations Transplacental Carcinogenesis Study

**CAS Number: AIDSTHERAPEU** 

Date Report Requested: 06/29/2009 Time Report Requested: 16:30:20 First Dose M/F: NA / 07/10/03

6 (13%)

(46)

Lab: NCTR

C57BL/6N XC3H/HEN MTV-NCTR MICE FEMALE	AZT-H to 0	AZT-M to 0	AZT-L to 0	AZT-H/3TC-H to 0	AZT-M/3TC-M to 0	AZT-L/3TC-L to (
Degeneration, Hyaline				2 (4%)		
Infiltration Cellular, Lymphocyte Inflammation, Chronic Active		4 (00()	1 (2%)	2 (4%)		2 (4%)
Mineralization Epithelium, Hyperplasia		1 (2%)	1 (2%)	2 (4%)		2 (4%)
CARDIOVASCULAR SYSTEM						
Blood Vessel Heart Cardiomyopathy Inflammation, Suppurative	(48) (47)	(46) (47)	(46) (46)	(48) (48)	(49) (50) 1 (2%)	(45) (48)
Inflammation, Chronic Active Mineralization Necrosis Polyarteritis	1 (2%)				1 (2%)	1 (2%)
ENDOCRINE SYSTEM						
Adrenal Cortex Accessory Adrenal Cortical Nodule Angiectasis	(47) 4 (9%)	(47) 4 (9%) 1 (2%)	(46) 3 (7%)	(47) 1 (2%)	(50) 1 (2%)	(47) 2 (4%)
Cyst Hypertrophy Vacuolization Cytoplasmic Subcapsular, Hyperplasia Adrenal Medulla	6 (13%) 46 (98%) (46)	4 (9%) 46 (98%) (45)	1 (2%) 6 (13%) 45 (98%) (43)	1 (2%) 44 (94%) (46)	3 (6%) 49 (98%) (47)	2 (4%) 1 (2%) 1 (2%) 47 (100%) (46)
Hyperplasia Islets, Pancreatic Hyperplasia Infiltration Cellular, Lymphocyte	(47) 2 (4%) 1 (2%)	(46) 3 (7%)	(46) 4 (9%)	(48) 1 (2%)	(49) 3 (6%)	(46) 4 (9%)
Parathyroid Gland Cyst Hyperplasia	(45)	(44)	(40) 1 (3%)	(38)	(40)	(36) 1 (3%)
Hypertrophy Infiltration Cellular, Lymphocyte Pituitary Gland Hemorrhage	(46)	(44)	(44) 1 (2%)	(46)	(49)	(45)
Pars Distalis, Angiectasis Pars Distalis, Cyst Pars Distalis, Hypotrologia	1 (2%) 1 (2%)	1 (2%) 2 (5%)	1 (2%) 6 (14%) 7 (16%)	2 (4%) 3 (7%)	1 (2%) 2 (4%)	2 (4%)

10 (22%)

(47)

1 (2%)

**TDMS No.** 20311 - 02 Test Type: CHRONIC

Species/Strain: MICE/B6C3F1/NCTR

Pars Distalis, Hyperplasia

Rathke's Cleft, Dilatation

Thyroid Gland

Ćyst

Route: IN-UTERO

7 (16%)

(46)

10 (22%)

(47)

11 (22%)

(50)

1 (2%)

10 (23%)

(46)

a - Number of animals examined microscopically at site and number of animals with lesion

AZT/Drug Combinations Transplacental Carcinogenesis Study

CAS Number: AIDSTHERAPEU

Date Report Requested: 06/29/2009 Time Report Requested: 16:30:20 First Dose M/F: NA / 07/10/03

Lab: NCTR

C57BL/6N XC3H/HEN MTV-NCTR MICE FEMALE	AZT-H to 0	AZT-M to 0	AZT-L to 0	AZT-H/3TC-H to 0	AZT-M/3TC-M to 0	AZT-L/3TC-L to (
Ectopic Thymus Infiltration Cellular, Lymphocyte Inflammation, Chronic Active	4 (9%)		1 (2%)	2 (4%)	1 (2%)	
Polyarteritis C-cell, Hyperplasia Follicle, Degeneration Follicular Cell, Hyperplasia Follicular Cell, Hypertrophy	9 (19%)	4 (9%)	7 (15%) 1 (2%)	1 (2%) 8 (17%) 1 (2%)	4 (8%) 2 (4%) 1 (2%)	6 (13%)
GENERAL BODY SYSTEM						
Tissue NOS Hemorrhage Infiltration Cellular, Lymphocyte Abdominal, Fibrosis Abdominal, Inflammation, Chronic Active	(1)	(2)	(1)	(1) 1 (100%) 1 (100%)	(2)	(0)
Abdominal, Keratin Cyst Fat, Necrosis	1 (100%)					
GENITAL SYSTEM						
Clitoral Gland	(46)	(43)	(44)	(44)	(49)	(44)
Atrophy	2 (4%)			1 (2%)		1 (2%)
Degeneration	39 (85%)	41 (95%)	41 (93%)	42 (95%)	45 (92%)	41 (93%)
Inflammation, Suppurative		4>	1		4>	
Ovary	(47)	(45) 1 (2%)	(45)	(48)	(50)	(43)
Angiectasis Atrophy	44 (94%)	39 (87%)	44 (98%)	39 (81%)	42 (84%)	36 (84%)
Cyst	13 (28%)	11 (24%)	14 (31%)	15 (31%)	42 (84%) 17 (34%)	13 (30%)
Cyst Dermoid	13 (20%)	11 (2470)	14 (3170)	13 (3170)	17 (3470)	13 (3070)
Hematocyst		2 (4%)		4 (8%)	1 (2%)	3 (7%)
Infiltration Cellular, Lymphocyte		2 (4%)		(===)	( /	- ( )
Inflammation, Chronic Active		, ,				
Bilateral, Cyst	4 (9%)	4 (9%)	3 (7%)	1 (2%)	2 (4%)	3 (7%)
Fat, Necrosis		- 4				1 (2%)
Germinal Epithelium, Hyperplasia		2 (4%)				
Parenchymal Cell, Degeneration Uterus	(47)	(47)	(46)	(48)	(50)	(46)
Angiectasis	(47)	(47)	1 (2%)	(40)	1 (2%)	1 (2%)
Autolysis			1 (2/0)		1 (270)	1 (2/0)
Hydrometra	6 (13%)	4 (9%)	5 (11%)	6 (13%)	1 (2%)	1 (2%)
Thrombosis	` ,		1 (2%)	` ,		
Endometrium, Hyperplasia, Cystic	41 (87%)	42 (89%)	38 (83%)	41 (85%)	49 (98%)	41 (89%)

TDMS No. 20311 - 02 Test Type: CHRONIC

Species/Strain: MICE/B6C3F1/NCTR

a - Number of animals examined microscopically at site and number of animals with lesion

 $\label{eq:AZT/Drug} \textbf{Combinations Transplacental Carcinogenesis Study}$ 

CAS Number: AIDSTHERAPEU

Date Report Requested: 06/29/2009 Time Report Requested: 16:30:20 First Dose M/F: NA / 07/10/03

Lab: NCTR

Species/Strain: MICE/B6C3F1/NCTR	

TDMS No. 20311 - 02 Test Type: CHRONIC

FEMALE	AZT-H to 0	AZT-M to 0	AZT-L to 0	AZT-H/3TC-H to 0	AZT-M/3TC-M to 0	AZT-L/3TC-L to (
HEMATOPOIETIC SYSTEM						
Bone Marrow	(46)	(47)	(46)	(46)	(50)	(46)
Hyperplasia		3 (6%)	2 (4%)		3 (6%)	1 (2%)
Pigmentation				1 (2%)		
Lymph Node	(8)	(12)	(5)	(5)	(10)	(9)
Cyst					1 (10%)	
Hemorrhage		1 (8%)			1 (10%)	
Hyperplasia, Lymphoid		1 (8%)				
Axillary, Autolysis						
Axillary, Hyperplasia, Lymphoid	2 (25%)		1 (20%)			
Bronchial, Autolysis						
Iliac, Autolysis						
Lumbar, Autolysis						
Lumbar, Cyst					4 (400()	
Lumbar, Fibrosis	0 (050()	4 (00()		4 (000()	1 (10%)	0 (000()
Lumbar, Hyperplasia, Lymphoid	2 (25%)	1 (8%)		1 (20%)	1 (10%)	2 (22%)
Lumbar, Infiltration Cellular, Plasma Cell				1 (20%)		
Lumbar, Infiltration Cellular, Polymorphonuclear						
Lumbar, Inflammation, Chronic Active						
Lumbar, Polyarteritis						
Mediastinal, Autolysis						
Mediastinal, Autorysis  Mediastinal, Hyperplasia, Lymphoid				1 (20%)		2 (22%)
Mediastinal, Infiltration Cellular, Plasma Cell				1 (2078)		2 (22 /0)
Pancreatic, Hyperplasia, Lymphoid			1 (20%)		1 (10%)	
Renal, Autolysis			1 (2070)		1 (1070)	
Renal, Hyperplasia, Lymphoid	2 (25%)	1 (8%)		1 (20%)		2 (22%)
Renal, Infiltration Cellular, Plasma Cell	= (=070)	. (373)		1 (20%)		_ (==70)
Renal, Infiltration Cellular, Polymorphonuclear				( /		
Sinus, Dilatation		2 (17%)				
Lymph Node, Mandibular	(47)	(44)	(46)	(48)	(49)	(45)
Autolysis						
Erythrophagocytosis		1 (2%)				
Hyperplasia, Lymphoid	9 (19%)	9 (20%)	12 (26%)	12 (25%)	16 (33%)	15 (33%)
Infiltration Cellular, Plasma Cell						1 (2%)
Infiltration Cellular, Polymorphonuclear					1 (2%)	
Pigmentation	(45)	(40)	(45)	(45)	(40)	(40)
Lymph Node, Mesenteric	(45)	(46)	(45)	(45)	(48)	(46)
Angiectasis	1 (2%)					1 (2%)
Autolysis	1 (2%)		4 (20()			
Cyst			1 (2%)			
Hematopoietic Cell Proliferation			2 (40/)	1 (20/)		
Hemorrhage			2 (4%)	1 (2%)		

a - Number of animals examined microscopically at site and number of animals with lesion

 $\label{eq:AZT/Drug} \textbf{Combinations Transplacental Carcinogenesis Study}$ 

CAS Number: AIDSTHERAPEU

Date Report Requested: 06/29/2009 Time Report Requested: 16:30:20 First Dose M/F: NA / 07/10/03

Lab: NCTR

Species/Strain: MICE/B6C3F1/NCTR	
	•

TDMS No. 20311 - 02 Test Type: CHRONIC

Hyperplasia   Hyperplasia   1 (2%)   16 (36%)   21 (47%)   23 (48%)   20 (43%)   17 (37%)   16 (36%)   21 (47%)   23 (48%)   20 (43%)   17 (37%)   1 (2%)	C57BL/6N XC3H/HEN MTV-NCTR MICE FEMALE	AZT-H to 0	AZT-M to 0	AZT-L to 0	AZT-H/3TC-H to 0	AZT-M/3TC-M to 0	AZT-L/3TC-L to
Hyperplasia, Lymphoid   16 (38%)   17 (37%)   16 (38%)   21 (47%)   22 (48%)   20 (43%)   1 (2%)   1	Hyperplasia		1 (2%)				
Infiltration Cellular, Histocyte (2 (4%) 1 (2%) 2 (4%) 1 (2%) 3 (7%) 2 (4%) 3 (7%) 1 (2%) 1 (2%) 1 (2%) 3 (7%) 2 (4%) 3 (7%) 1 (2%) 1 (2%) 3 (7%) 2 (4%) 3 (7%) 1 (2%) 1 (2%) 3 (7%) 2 (4%) 3 (7%) 1 (2%) 1 (	Hyperplasia, Lymphoid	16 (36%)	17 (37%)	16 (36%)	21 (47%)	23 (48%)	20 (43%)
Infilitration Cellular, Polymorphonuclear Inflammation, Chronic Active Thrombosis Inflammation, Chronic Active Thrombosis Sinus, Dilatation 1 (2%) (47) (47) (46) (47) (50) (48) (48) (48) (47) (50) (48) (48) (48) (47) (46) (47) (46) (47) (46) (47) (48) (48) (48) (48) (48) (48) (48) (48	Infiltration Cellular, Histiocyte	2 (4%)	1 (2%)	2 (4%)	1 (2%)		1 (2%)
Inflammation, Chronic Active Thrombosis Sinus, Dilatation 1 (2%) (47) (47) (46) (47) (50) (48) (48) (47) (50) (48) (48) (47) (47) (48) (48) (47) (50) (48) (48) (47) (48) (48) (47) (48) (48) (47) (48) (48) (48) (48) (48) (48) (48) (48	Infiltration Cellular, Plasma Cell		1 (2%)	1 (2%)	3 (7%)		3 (7%)
Thrombosis Sinus, Dilatation 1 (2%) (47) (47) (46) (47) (50) (48) (48) Spleen (47) (47) (47) (46) (47) (50) (48) (48) Autolysis 1 (2%) Erythrophagocytosis Hematopoetic Cell Proliferation 11 (23%) 13 (28%) 8 (17%) 13 (28%) 17 (34%) 10 (21%) Hemotrhage 28 (60%) 25 (53%) 25 (54%) 27 (57%) 32 (64%) 31 (65%) Necrosis 1 (2%) 1 (		2 (4%)		1 (2%)		2 (4%)	
Sinus   Diletation   1 (2%)   (47)					2 (4%)		
Spleen		4 (00()		4 (00/)			
Autolysis			(47)		(47)	(50)	(40)
Enthrophagocytosis Hematopoletic Cell Proliferation Hospitals, Lymphoid 28 (60%) 25 (53%) 25 (54%) 27 (57%) 32 (64%) 31 (65%) Necrosis Pigmentation Thrombosis Thymus (46) (42) (44) (45) Angiectasis Algueration Atrophy 16 (35%) 12 (29%) 13 (30%) 18 (40%) 13 (28%) 15 (35%) 16 (47) (43) Angiectasis 1 (2%) Autolysis 1 (2%) Hyperplasia, Lymphoid 15 (11%) Mineralization 1 (2%) Fat, Necrosis 1 (2%)  NTEGUMENTARY SYSTEM  Mammary Gland Galactocele Lactation Metaplasia, Squamous Alveolus, Hyperplasia 1 (2%) Metaplasia, Squamous Alveolus, Hyperplasia 1 (2%) Metaplasia, Squamous Alveolus, Hyperplasia 1 (2%) 1 (2%) Metaplasia, Cymphocyte Inflammation, Chronic Active Ulcer  MUSCULOSKELETAL SYSTEM  Bone, Femur Fibro-OSSeous Lesion 1 (2%) 1 (2%			(47)	(46)	(47)	(50)	(48)
Hemotrhage		1 (2%)					
Hemorrhage Hyperplasia, Lymphoid 28 (60%) 25 (53%) 25 (54%) 27 (57%) 32 (64%) 31 (65%) Necrosis 1 (2%) 1 (2	Homotopoiotic Coll Proliferation	11 (22%)	13 (20%)	Q (170/)	12 (28%)	17 (2/10/.)	10 (21%)
Hyperplasia, Lymphoid 28 (60%) 25 (53%) 25 (64%) 27 (57%) 32 (64%) 31 (65%) Necrosis Pigmentation Thrombosis Thymus (46) (42) (44) (45) (47) (43) Angiectasis 1(2%) Atrophy 16 (35%) 12 (29%) 13 (30%) 18 (40%) 13 (28%) 15 (35%) Autolyis 1 (2%) Hyperplasia, Lymphoid 5 (11%) 6 (14%) 12 (27%) 3 (7%) 9 (19%) 7 (16%) Mineralization 1 (2%) Fat, Necrosis 1 (2%)  NTEGUMENTARY SYSTEM  Mammary Gland (47) (46) (45) (45) (50) (45) Galactocele Lactation 1 (2%) Metaplasia, Squarnous Alveolus, Hyperplasia 1 (2%) 2 (4%) 1 (2%) 1 (2%) Nterplasia, Lymphoid 1 (2%) 1 (2%) Metaplasia, Squarnous Alveolus, Hyperplasia 1 (2%) 2 (4%) 1 (2%) 1 (2%) Skin (48) (47) (46) (48) (50) (46) Fibrosis Infiltration Cellular, Lymphocyte Inflammation, Chronic Active Uicer 1 (2%)  MUSCULOSKELETAL SYSTEM  Bone, Femur (48) (47) (47) (48) (51) (48) (51) (48) Fibro-Ossseous Lesion (48) (47) (47) (48) (51) (48)	Hemorrhage	11 (23 %)	13 (26%)	8 (17 %)	13 (20%)	17 (3470)	10 (2170)
Necrosis		28 (60%)	25 (53%)	25 (54%)	27 (57%)	32 (64%)	31 (65%)
Pigmentation		20 (0070)		23 (3470)	21 (31 70)	32 (0470)	31 (0370)
Thrombosis Thymus (46) (42) (44) (45) (47) (43) Anglectasis Arrophy 16 (35%) 12 (29%) 13 (30%) 18 (40%) 13 (28%) 15 (35%) Autolyisis 1 (2%) Hyperplasia, Lymphoid 5 (11%) 6 (14%) 12 (27%) 3 (7%) 9 (19%) 7 (16%) Mineralization 1 (2%) Fat, Necrosis 1 (2%)  NTEGUMENTARY SYSTEM  Mammary Gland (47) (46) (45) (45) (50) (45) Galactocele Lactation 1 (2%) 2 (4%) Metaplasia, Squamous Alveolus, Hyperplasia 1 (2%) 2 (4%) 1 (2%) 1 (2%) 1 (2%)  Skin (48) (47) (46) (48) (50) (50) (46) Inflarmation, Chronic Active 1 (2%) Ulcer  MUSCULOSKELETAL SYSTEM  Bone, Femur Fibro-Osseous Lesion 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%)			(270)	1 (2%)			
Angiectasis Atrophy Atrophy Atrophy Atrophy Atrophy Autolysis Hyperplasia, Lymphoid Hyperplasia, Lymphoid Hyperplasia, Lymphoid Hyperplasia, Lymphoid Hyperplasia, Lymphoid Hyperplasia, Lymphoid Higher Hyperplasia Hyperplasia, Lymphoid Higher Hyperplasia Hype				(= / - /			
Angiectasis Atrophy Atrophy Atrophy Atrophy Atrophy Autolysis Hyperplasia, Lymphoid Hyperplasia, Lymphoid Hyperplasia, Lymphoid Hyperplasia, Lymphoid Hyperplasia, Lymphoid Hyperplasia, Lymphoid Higher Hyperplasia Hyperplasia, Lymphoid Higher Hyperplasia Hype	Thymus	(46)	(42)	(44)	(45)	(47)	(43)
Autolysis		` '					
Hyperplasia, Lymphoid 5 (11%) 6 (14%) 12 (27%) 3 (7%) 9 (19%) 7 (16%) Mineralization Fat, Necrosis 1 (2%) 1 (2%)  NTEGUMENTARY SYSTEM  Mammary Gland (47) (46) (45) (45) (50) (45) (50) (45) Galactocele Lactation 1 (2%) 2 (4%) 1 (2%) 1 (2%) 1 (2%) Skin (48) (47) (46) (48) (50) (50) (46) Fibrosis 1 (2%) 1 (2%)  MUSCULOSKELETAL SYSTEM  Bone, Femur (48) (48) (47) (47) (48) (51) (48) (51) (48) (51) (48) (50) (51) (48) (50) (51) (48) (50) (51) (48) (50) (51) (48) (50) (51) (51) (51) (51) (51) (51) (51) (51			12 (29%)	13 (30%)	18 (40%)	13 (28%)	15 (35%)
Mineralization Fat, Necrosis 1 (2%)  NTEGUMENTARY SYSTEM  Mammary Gland (47) (46) (45) (45) (50) (45)  Galactocele Lactation 1 (2%) 2 (4%) Metaplasia, Squamous Alveolus, Hyperplasia 1 (2%) 2 (4%) 1 (2%) 1 (2%) Skin (48) (47) (46) (48) (50) (46) Fibrosis 1 (2%) Infilitation Cellular, Lymphocyte Inflammation, Chronic Active 1 (2%) Ulcer 1 (2%)  WUSCULOSKELETAL SYSTEM  Bone, Femur (48) (47) (47) (48) (51) (48)  Bone, Femur (48) (50) 1 (2%)  MUSCULOSKELETAL SYSTEM		1 (2%)					
Fat, Necrosis			6 (14%)	12 (27%)	3 (7%)	9 (19%)	7 (16%)
NTEGUMENTARY SYSTEM  Mammary Gland (47) (46) (45) (45) (50) (45) Galactocele 1(2%) 2 (4%) Lactation 1 (2%) 2 (4%) Metaplasia, Squamous Alveolus, Hyperplasia 1 (2%) 2 (4%) 1 (2%) 1 (2%) 1 (2%) Skin (48) (47) (46) (48) (50) (46) Fibrosis 10filtration Cellular, Lymphocyte Inflammation, Chronic Active 1 (2%) Ulcer 1 (2%)  MUSCULOSKELETAL SYSTEM  Bone, Femur (48) (48) (47) (47) (48) (51) (48) Fibro-Osseous Lesion 1 (2%) 1 (2%) 1 (2%) 1 (2%)							
Mammary Gland     (47)     (46)     (45)     (45)     (50)     (45)       Galactocele     1 (2%)     2 (4%)     1 (2%)     1 (2%)     1 (2%)       Metaplasia, Squamous     1 (2%)     2 (4%)     1 (2%)     1 (2%)     1 (2%)     1 (2%)       Skin     (48)     (47)     (46)     (48)     (50)     (46)       Fibrosis     1 (2%)     1 (2%)     1 (2%)       Infiltration Cellular, Lymphocyte     1 (2%)     1 (2%)     1 (2%)       Ulcer     1 (2%)     1 (2%)     1 (2%)    WUSCULOSKELETAL SYSTEM  Bone, Femur  Fibro-Osseous Lesion  (48)  (48)  (47)  (47)  (47)  (47)  (48)  (48)  (51)  (48)  (51)  (48)  (51)  (48)  (48)  (47)  (48)  (47)  (47)  (47)  (48)  (47)  (48)  (47)  (48)  (48)  (47)  (48)  (48)  (47)  (48)  (48)  (47)  (48)  (48)  (48)  (48)  (48)  (47)  (48)  (48)  (48)  (48)  (48)  (48)  (48)  (48)  (48)  (48)  (48)  (48)  (48)  (48)  (48)  (47)  (48)  (48)  (48)  (48)  (48)  (48)  (48)  (48)  (48)  (48)  (48)  (48)  (48)  (48)  (48)  (47)  (48)	Fat, Necrosis	1 (2%)					
Galactocele Lactation Metaplasia, Squamous Alveolus, Hyperplasia 1 (2%) 2 (4%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%)  MUSCULOSKELETAL SYSTEM  Bone, Femur Fibro-Osseous Lesion  4 (48) 4 (47) 4 (47) 4 (47) 4 (48) 4 (51) 4 (48) 5 (51) 4 (48) 5 (47) 4 (47) 4 (47) 4 (48) 4 (51) 4 (48) 5 (10) 6 (48) 6 (48) 6 (47) 6 (48) 6 (47) 6 (48) 6 (47) 6 (48) 6 (47) 6 (48) 6 (47) 6 (48) 6 (47) 6 (48) 6 (47) 6 (48) 6 (48) 6 (51) 6 (48) 6 (48) 6 (51) 6 (48) 6 (48) 6 (47) 6 (48) 6 (47) 6 (48) 6 (47) 6 (48) 6 (47) 6 (48) 6 (48) 6 (47) 6 (48) 6 (48) 6 (47) 6 (48) 6 (48) 6 (48) 6 (47) 6 (48) 6 (48) 6 (47) 6 (48) 6 (48) 6 (47) 6 (48) 6 (48) 6 (47) 6 (48) 6 (47) 6 (48) 6 (48) 6 (47) 6 (48) 6 (48) 6 (47) 6 (48) 6 (48) 6 (47) 6 (48) 6 (47) 6 (48) 6 (47) 6 (48) 6 (47) 6 (48) 6 (47) 6 (48) 6 (47) 6 (48) 6 (47) 6 (48) 6 (47) 6 (48) 6 (48) 6 (47) 6 (48) 6 (47) 6 (48) 6 (47) 6 (48) 6 (47) 6 (48) 6 (47) 6 (48) 6 (48) 6 (47) 6 (48) 6 (47) 6 (48) 6 (47) 6 (48) 6 (4	NTEGUMENTARY SYSTEM						
Lactation Metaplasia, Squamous Alveolus, Hyperplasia 1 (2%) 2 (4%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%)  Ulcer     MUSCULOSKELETAL SYSTEM    Bone, Femur		(47)	(46)	(45)	(45)		(45)
Metaplasia, Squamous Alveolus, Hyperplasia 1 (2%) 2 (4%) 1 (2%) 1 (2%) 1 (2%) Skin (48) (47) (46) (48) (50) (46) Fibrosis Infiltration Cellular, Lymphocyte Inflammation, Chronic Active 1 (2%) Ulcer 1 (2%)  MUSCULOSKELETAL SYSTEM  Bone, Femur Fibro-Osseous Lesion (48) (47) (47) (48) (51) (48) Fibro-Osseous Lesion 1 (2%) 1 (2%) 1 (2%)			4 (00()	0 (404)		1 (2%)	
Alveolus, Hyperplasia 1 (2%) 2 (4%) 1 (2%) 1 (2%) 1 (2%) (48) (50) (46)    Skin (48) (47) (46) (48) (50) (46)    Fibrosis			1 (2%)	2 (4%)			
Skin (48) (47) (46) (48) (50) (46)  Fibrosis 1 (2%)  Infiltration Cellular, Lymphocyte Inflammation, Chronic Active 1 (2%)  Ulcer 1 (2%)  MUSCULOSKELETAL SYSTEM  Bone, Femur (48) (47) (47) (48) (51) (48)  Fibro-Osseous Lesion 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%)	Metapiasia, Squamous	4 (20/)	2 (40/)	1 (20()	4 (20/)	4 (20/)	
Fibrosis Infiltration Cellular, Lymphocyte Inflammation, Chronic Active 1 (2%) Ulcer 1 (2%)  MUSCULOSKELETAL SYSTEM  Bone, Femur (48) (47) (47) (48) (51) (48) Fibro-Osseous Lesion 1 (2%) 1 (2%) 1 (2%) 1 (2%)							(46)
Infiltration Cellular, Lymphocyte Inflammation, Chronic Active	-	(48)	(47)	(40)		(50)	(40)
Inflammation, Chronic Active 1 (2%) Ulcer 1 (2%)  MUSCULOSKELETAL SYSTEM  Bone, Femur (48) (47) (47) (48) (51) (48) Fibro-Osseous Lesion 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%)					1 (270)		
Ulcer 1 (2%)  MUSCULOSKELETAL SYSTEM  Bone, Femur (48) (47) (47) (48) (51) (48) (51) (48) (51) (2%) (48) (51) (2%) (48) (49) (49) (49) (49) (49) (49) (49) (49			1 (2%)				
MUSCULOSKELETAL SYSTEM  Bone, Femur (48) (47) (47) (48) (51) (48) Fibro-Osseous Lesion 1 (2%) 1 (2%) 1 (2%) 1 (2%)			1 (2%)				
Bone, Femur (48) (47) (47) (48) (51) (48) Fibro-Osseous Lesion 1 (2%) 1 (2%) 1 (2%) 1 (2%)			( /				
Fibro-Osseous Lesion 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%)	MUSCULOSKELETAL SYSTEM						
Fibro-Osseous Lesion 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%)	Bone, Femur	(48)	(47)	(47)	(48)	(51)	(48)
		( /			1 (2%)		
		(0)	(0)	(0)	(1)	(1)	(1)

a - Number of animals examined microscopically at site and number of animals with lesion

AZT/Drug Combinations Transplacental Carcinogenesis Study

CAS Number: AIDSTHERAPEU

Date Report Requested: 06/29/2009 Time Report Requested: 16:30:20 First Dose M/F: NA / 07/10/03

Lab: NCTR

TDMS No. 20311 - 02 Test Type: CHRONIC

C57BL/6N XC3H/HEN MTV-NCTR MICE FEMALE	AZT-H to 0	AZT-M to 0	AZT-L to 0	AZT-H/3TC-H to 0	AZT-M/3TC-M to 0	AZT-L/3TC-L to
NERVOUS SYSTEM						
Brain, Brain Stem	(47)	(46)	(46)	(47)	(49)	(47)
Compression Degeneration	1 (2%)	3 (7%)	1 (2%)	1 (2%)	2 (4%)	
Hemorrhage			1 (2%)			
Brain, Cerebellum	(47)	(46)	(46)	(47)	(49)	(47)
Hemorrhage	(,	(15)	(1-)	( ,	(12)	(,
Infiltration Cellular, Lymphocyte						
Vacuolization Cytoplasmic						
Meninges, Infiltration Cellular, Lymphocyte	1 (2%)					
Ventricle, Dilatation Brain, Cerebrum	(47)	(46)	(46)	(47)	(49)	(47)
Cyst Epithelial Inclusion	(47)	(40)	(40)	(47)	(43)	(47)
Hemorrhage						
Mineralization	22 (47%)	22 (48%)	26 (57%)	25 (53%)	25 (51%)	28 (60%)
Meninges, Infiltration Cellular, Lymphocyte Ventricle, Dilatation	1 (2%)					
Peripheral Nerve	(0)	(0)	(0)	(0)	(1)	(1)
Axon, Degeneration						
Spinal Cord	(0)	(0)	(0)	(0)	(1)	(1)
Degeneration Inflammation, Chronic Active						
Axon, Degeneration						
RESPIRATORY SYSTEM	(40)	()	(10)	(12)	(72)	(10)
Lung	(48)	(47)	(46)	(48)	(50)	(48)
Autolysis Congestion	1 (2%)	1 (2%)			1 (2%)	
Crystals	3 (6%)	3 (6%)	1 (2%)	2 (4%)	1 (2/0)	2 (4%)
Hemorrhage	1 (2%)	3 (370)	(270)	2 (170)	1 (2%)	2 (170)
Infiltration Cellular, Histiocyte	4 (8%)	4 (9%)	1 (2%)	2 (4%)	( /	3 (6%)
Infiltration Cellular, Lymphocyte	14 (29%)	13 (28%)	14 (30%)	14 (29%)	16 (32%)	14 (29%)
Inflammation, Chronic	4 (00()		0 (40()	1 (2%)	4 (00()	4 (00()
Inflammation, Chronic Active Metaplasia, Osseous	1 (2%)		2 (4%)		1 (2%)	1 (2%)
Alveolar Epithelium, Hyperplasia	1 (2%)	2 (4%)	1 (2%)	1 (2%)	2 (4%)	1 (2%)
Bronchiole, Hyperplasia	. (270)	~ (±/0)	. (270)	· (2/0)	- ( + /0)	. (270)
Nose	(48)	(47)	(46)	(48)	(51)	(46)
Inflammation, Suppurative						
Posterior To Upper Incisor, Dysplasia		1 (2%)				

a - Number of animals examined microscopically at site and number of animals with lesion

AZT/Drug Combinations Transplacental Carcinogenesis Study

CAS Number: AIDSTHERAPEU

Date Report Requested: 06/29/2009 Time Report Requested: 16:30:20 First Dose M/F: NA / 07/10/03

Lab: NCTR

C57BL/6N XC3H/HEN MTV-NCTR MICE FEMALE	AZT-H to 0	AZT-M to 0	AZT-L to 0	AZT-H/3TC-H to 0	AZT-M/3TC-M to 0	AZT-L/3TC-L to 0
SPECIAL SENSES SYSTEM						
Eye Cataract Degeneration Inflammation, Chronic Active	(46) 1 (2%)	(45) 1 (2%)	(46) 1 (2%)	(46) 1 (2%)	(49) 1 (2%)	(45) 1 (2%)
Metaplasia, Squamous Bilateral, Cataract Cornea, Inflammation, Chronic Active Cornea, Necrosis Cornea, Ulcer	1 (2%) 1 (2%)	1 (2%) 1 (2%)		1 (2%)		1 (2%) 1 (2%)
Retina, Degeneration Harderian Gland	(46)	(47)	(46)	(47)	(50)	(46)
Cyst Infiltration Cellular, Lymphocyte	6 (13%)	8 (17%)	6 (13%)	4 (9%)	1 (2%) 4 (8%)	2 (4%)
Inflammation, Chronic	0 (13%)	0 (17%)	0 (13%)	4 (9%)	4 (0%)	2 (4%)
Inflammation, Chronic Active Acinus, Degeneration Acinus, Hyperplasia Epithelium, Hyperplasia	1 (2%)			1 (2%)	1 (2%)	1 (2%)
JRINARY SYSTEM						
Kidney Amyloid Deposition Hemorrhage	(46)	(46)	(46) 1 (2%) 1 (2%)	(46)	(50)	(46)
Hyaline Droplet Hydronephrosis Hyperplasia, Lymphoid	1 (2%)	2 (4%)	1 (2%)	1 (2%)	1 (2%)	2 (4%)
Infiltration Cellular, Lymphocyte Inflammation, Chronic Active	12 (26%)	16 (35%)	15 (33%)	16 (35%)	17 (34%)	13 (28%)
Metaplasia, Osseous Nephropathy Polyarteritis	3 (7%) 25 (54%)	27 (59%)	3 (7%) 23 (50%)	1 (2%) 18 (39%)	2 (4%) 23 (46%)	1 (2%) 26 (57%)
Adventitia, Inflammation, Chronic Active Adventitia, Fat, Necrosis Urinary Bladder	(46)	(46)	1 (2%) 1 (2%) (46)	(46)	(49)	(45)
Edema	(40)	1 (2%)	(46)	(40)	(49)	(45)
Infiltration Cellular, Lymphocyte Inflammation, Chronic Active Polyarteritis	20 (43%)	19 (41%) 1 (2%)	21 (46%)	22 (48%)	26 (53%)	24 (53%)
Lumen, Dilatation						1 (2%)

TDMS No. 20311 - 02 Test Type: CHRONIC

Species/Strain: MICE/B6C3F1/NCTR

a - Number of animals examined microscopically at site and number of animals with lesion

**TDMS No.** 20311 - 02

Test Type: CHRONIC

Route: IN-UTERO

Species/Strain: MICE/B6C3F1/NCTR

#### P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

 $\label{eq:AZT/Drug} \ Combinations \ Transplacental \ Carcinogenesis \ Study$ 

CAS Number: AIDSTHERAPEU

Date Report Requested: 06/29/2009 Time Report Requested: 16:30:20

First Dose M/F: NA / 07/10/03

Lab: NCTR

C57BL/6N XC3H/HEN MTV-NCTR MICE AZT-H to 0 AZT-M to 0 AZT-L to 0 AZT-H/3TC-H to 0 AZT-M/3TC-M to 0 AZT-L/3TC-L to 0 FEMALE

AZT/Drug Combinations Transplacental Carcinogenesis Study

CAS Number: AIDSTHERAPEU

Date Report Requested: 06/29/2009 Time Report Requested: 16:30:20 First Dose M/F: NA / 07/10/03

Lab: NCTR

C57BL/6N XC3H/HEN MTV-NCTR MICE FEMALE	AZTH/3TCH/NVPH/0	AZTM/3TCM/NVPM/0	AZTL/3TCL/NVPL/0	AZTH/3TCH/NFVH/0	AZTM/3TCM/NFVM/0	AZTL/3TCL/NFVL/
Disposition Summary						
Animals Initially in Study Early Deaths	49	48	48	26	49	50
Moribund Sacrifice Natural Death	5 4	7 2	12 2	4 1	3 1	8 5
Survivors Moribund Sacrifice Natural Death		2		2	5 1	4
Terminal Sacrifice Harvest Animals Examined Microscopically	39 1 49	34 3 48	31 3 48	16 3 26	37 2 49	30 3 50
LIMENTARY SYSTEM						
Esophagus Gallbladder	(48) (45)	(47) (45)	(47) (45)	(25) (25)	(48) (47)	(49) (46)
Cyst Degeneration, Hyaline Infiltration Cellular, Lymphocyte			1 (2%)	1 (4%) 1 (4%)		1 (2%)
Inflammation, Chronic Intestine Large, Cecum Hyperplasia, Lymphoid Serosa, Hyperplasia	(45) 1 (2%)	(46) 3 (7%)	(45)	(25)	(47) 2 (4%)	(45) 3 (7%)
Intestine Large, Colon Intestine Large, Rectum	(45) (45)	(46) (46)	(46) (46)	(25) (25)	(47) (47)	(46) (46)
Hyperplasia, Lymphoid Intestine Small, Duodenum Diverticulum	(45)	(46)	(46)	(25)	(47)	(45)
Intestine Small, Ileum Hyperplasia, Lymphoid Inflammation, Chronic Active	(45)	(46)	(46)	(25)	(47)	(45)
Intestine Small, Jejunum Hyperplasia, Lymphoid	(46)	(46)	(46)	(25)	(47)	(45) 2 (4%)
Epithelium, Hyperplasia Liver Angiectasis	(47)	(47) 1 (2%)	(46)	(26)	(48)	1 (2%) (50) 2 (4%)
Autolysis Basophilic Focus Basophilic Focus, Multiple	7 (15%)	4 (9%)	3 (7%)	1 (4%) 1 (4%)	1 (2%) 2 (4%)	1 (2%)
Clear Cell Focus Congestion Cyst			1 (2%)		1 (2%)	

TDMS No. 20311 - 02 Test Type: CHRONIC

Species/Strain: MICE/B6C3F1/NCTR

a - Number of animals examined microscopically at site and number of animals with lesion

 $\label{eq:AZT/Drug} \textbf{Combinations Transplacental Carcinogenesis Study}$ 

CAS Number: AIDSTHERAPEU

Date Report Requested: 06/29/2009 Time Report Requested: 16:30:20 First Dose M/F: NA / 07/10/03

Lab: NCTR

Species/Strain: MICE/B6C3F1/NCTI	₹

**TDMS No.** 20311 - 02

Test Type: CHRONIC

C57BL/6N XC3H/HEN MTV-NCTR MICE FEMALE	AZTH/3TCH/NVPH/0	AZTM/3TCM/NVPM/0	AZTL/3TCL/NVPL/0	AZTH/3TCH/NFVH/0	AZTM/3TCM/NFVM/0	AZTL/3TCL/NFVL/0
Cyst Multilocular			1 (2%)			
Deformity	1 (2%)					
Eosinophilic Focus		1 (2%)		1 (4%)	3 (6%)	
Eosinophilic Focus, Multiple						
Fatty Change		1 (2%)				
Hematocyst						
Hematopoietic Cell Proliferation			2 (4%)		2 (4%)	2 (4%)
Hemorrhage						
Hepatodiaphragmatic Nodule						
Infiltration Cellular, Histiocyte						
Infiltration Cellular, Lymphocyte	16 (34%)	12 (26%)	13 (28%)	6 (23%)	15 (31%)	13 (26%)
Inflammation, Chronic Active	3 (6%)	` ,	4 (9%)	4 (15%)	7 (Ì5%) <sup>′</sup>	1 (2%)
Mineralization	- ()		()	(,	(,	( /
Mixed Cell Focus	1 (2%)	1 (2%)		1 (4%)	1 (2%)	1 (2%)
Necrosis	1 (2%)	1 (2%)	1 (2%)	( ( , , , ,	3 (6%)	3 (6%)
Tension Lipidosis	9 (19%)	10 (21%)	7 (15%)	3 (12%)	5 (10%)	6 (12%)
Vacuolization Cytoplasmic	10 (21%)	24 (51%)	26 (57%)	11 (42%)	25 (52%)	19 (38%)
Mesentery	(3)	(8)	(1)	(5)	(7)	(7)
Cyst	(3)	(0)	(1)	(5)	(1)	(1)
Hematocyst						
Hemorrhage						1 (14%)
Infiltration Cellular, Lymphocyte					1 (14%)	1 (1470)
Fat, Necrosis	3 (100%)	8 (100%)	1 (100%)	5 (100%)	5 (71%)	5 (71%)
	` ,					
Pancreas	(47)	(46)	(45)	(25)	(46)	(47)
Cyst			1 (2%)		2 (4%)	4 (00()
Cytoplasmic Alteration						1 (2%)
Edema	(222)	(222()	00 (440)	40 (400)	(0.00()	12 (122)
Infiltration Cellular, Lymphocyte	14 (30%)	14 (30%)	20 (44%)	10 (40%)	14 (30%)	19 (40%)
Inflammation, Chronic Active						
Mineralization	1 (2%)					
Necrosis						
Acinus, Degeneration	3 (6%)		1 (2%)	2 (8%)	2 (4%)	3 (6%)
Duct, Dilatation						1 (2%)
Fat, Necrosis						
Salivary Glands	(46)	(47)	(47)	(25)	(47)	(47)
Infiltration Cellular, Lymphocyte	38 (83%)	36 (77%)	33 (70%)	21 (84%)	40 (85%)	36 (77%)
Polyarteritis						1 (2%)
Acinus, Degeneration						
Stomach, Forestomach	(47)	(46)	(46)	(25)	(47)	(47)
Hyperkeratosis	` ,	, ,	` ,	, ,	` '	` ,
Hyperplasia		1 (2%)				
Inflammation, Chronic Active		( /	1 (2%)			
Keratin Cyst		1 (2%)	- (=,=,			
Ulcer		1 (2%)				1 (2%)
Epithelium, Hyperplasia	4 (9%)	1 (2%)	3 (7%)		1 (2%)	1 (2%)
		· \~ /0/	O (1 /0)		(47)	· (~ /0)

a - Number of animals examined microscopically at site and number of animals with lesion

 $\label{lem:azt} \mbox{AZT/Drug Combinations Transplacental Carcinogenesis Study}$ 

CAS Number: AIDSTHERAPEU

Date Report Requested: 06/29/2009 Time Report Requested: 16:30:20 First Dose M/F: NA / 07/10/03

Lab: NCTR

C57BL/6N XC3H/HEN MTV-NCTR MICE FEMALE	AZTH/3TCH/NVPH/0	AZTM/3TCM/NVPM/0	AZTL/3TCL/NVPL/0	AZTH/3TCH/NFVH/0	AZTM/3TCM/NFVM/0	AZTL/3TCL/NFVL/0
Degeneration, Hyaline Infiltration Cellular, Lymphocyte Inflammation, Chronic Active Mineralization						
Epithelium, Hyperplasia			1 (2%)			
CARDIOVASCULAR SYSTEM						
Blood Vessel Heart Cardiomyopathy	(48) (49) 1 (2%)	(47) (47)	(47) (46)	(25) (25) 1 (4%)	(48) (48)	(50) (50) 1 (2%)
Inflammation, Suppurative Inflammation, Chronic Active Mineralization Necrosis		1 (2%)				
Polyarteritis						1 (2%)
ENDOCRINE SYSTEM						
Adrenal Cortex Accessory Adrenal Cortical Nodule Angiectasis	(48) 1 (2%)	(46) 1 (2%)	(45) 4 (9%)	(25)	(49) 1 (2%)	(48) 2 (4%)
Cyst	. (00)	. (00)		1 (4%)	1 (2%)	
Hypertrophy Vacuolization Cytoplasmic Subcapsular, Hyperplasia Adrenal Medulla	1 (2%) 46 (96%) (44)	1 (2%) 1 (2%) 46 (100%) (45)	2 (4%) 45 (100%) (43)	25 (100%) (25)	2 (4%) 47 (96%) (47)	1 (2%) 47 (98%) (46)
Hyperplasia Islets, Pancreatic Hyperplasia Infiltration Cellular, Lymphocyte	1 (2%) (47) 4 (9%)	(46) 4 (9%)	(45) 3 (7%)	(25)	1 (2%) (46) 1 (2%)	(47)
Parathyroid Gland Cyst	(41)	(44)	(38)	(21) 1 (5%)	(42)	(42)
Hyperplasia Hypertrophy	1 (2%)			, ,		
Infiltration Cellular, Lymphocyte Pituitary Gland Hemorrhage	1 (2%) (42)	1 (2%) (46)	1 (3%) (43)	1 (5%) (23)	(45)	(47)
Pars Distalis, Angiectasis Pars Distalis, Cyst	4 (10%) 4 (10%)	1 (2%)	1 (2%)		4 (9%)	1 (2%)
Pars Distalis, Gyst  Pars Distalis, Hyperplasia  Rathke's Cleft, Dilatation	13 (31%)	7 (15%) 1 (2%)	8 (19%)	2 (9%)	11 (24%)	11 (23%)
Thyroid Gland Cyst	(47) 1 (2%)	(45) 1 (2%)	(46) 1 (2%)	(25)	(48) 2 (4%)	(47) 1 (2%)

**TDMS No.** 20311 - 02

Test Type: CHRONIC

Species/Strain: MICE/B6C3F1/NCTR

a - Number of animals examined microscopically at site and number of animals with lesion

AZT/Drug Combinations Transplacental Carcinogenesis Study

CAS Number: AIDSTHERAPEU

Date Report Requested: 06/29/2009 Time Report Requested: 16:30:20 First Dose M/F: NA / 07/10/03

Lab: NCTR

C57BL/6N XC3H/HEN MTV-NCTR MICE FEMALE	AZTH/3TCH/NVPH/0	AZTM/3TCM/NVPM/0	AZTL/3TCL/NVPL/0	AZTH/3TCH/NFVH/0	AZTM/3TCM/NFVM/0	AZTL/3TCL/NFVL/
Ectopic Thymus Infiltration Cellular, Lymphocyte	1 (2%)	1 (2%) 3 (7%)	1 (2%) 1 (2%)	1 (4%)	1 (2%) 1 (2%)	5 (11%)
Inflammation, Chronic Active Polyarteritis				1 (4%)	1 (2%)	1 (2%)
C-cell, Hyperplasia Follicle, Degeneration Follicular Cell, Hyperplasia Follicular Cell, Hypertrophy	9 (19%) 1 (2%)	7 (16%)	9 (20%)	7 (28%)	4 (8%)	7 (15%)
ENERAL BODY SYSTEM						
Tissue NOS Hemorrhage Infiltration Cellular, Lymphocyte	(0)	(0)	(1)	(0)	(1)	(2)
Abdominal, Fibrosis Abdominal, Inflammation, Chronic Active Abdominal, Keratin Cyst Fat, Necrosis					1 (100%) 1 (100%)	1 (50%) 1 (50%) 1 (50%)
ENITAL SYSTEM						
Clitoral Gland	(46)	(46)	(46)	(25)	(47)	(46)
Clitoral Gland Atrophy		1 (2%)	1 (2%)		1 (2%)	
Clitoral Gland Atrophy Degeneration	(46) 45 (98%)	1 (2%) 43 (93%)	(46) 1 (2%) 42 (91%)	24 (96%)	(47) 1 (2%) 43 (91%)	(46) 42 (91%)
Clitoral Gland Atrophy Degeneration Inflammation, Suppurative Ovary		1 (2%)	1 (2%)		1 (2%)	
Clitoral Gland Atrophy Degeneration Inflammation, Suppurative Ovary Angiectasis	45 (98%) (48)	1 (2%) 43 (93%) 1 (2%) (47)	1 (2%) 42 (91%) (46)	24 (96%) 1 (4%) (25)	1 (2%) 43 (91%) (48)	42 (91%) (47)
Clitoral Gland Atrophy Degeneration Inflammation, Suppurative Ovary Angiectasis Atrophy	45 (98%) (48) 40 (83%)	1 (2%) 43 (93%) 1 (2%) (47) 42 (89%)	1 (2%) 42 (91%) (46) 38 (83%)	24 (96%) 1 (4%) (25) 23 (92%)	1 (2%) 43 (91%) (48) 43 (90%)	42 (91%) (47) 40 (85%)
Clitoral Gland Atrophy Degeneration Inflammation, Suppurative Ovary Angiectasis Atrophy Cyst	45 (98%) (48)	1 (2%) 43 (93%) 1 (2%) (47)	1 (2%) 42 (91%) (46)	24 (96%) 1 (4%) (25)	1 (2%) 43 (91%) (48)	42 (91%) (47) 40 (85%) 13 (28%)
Clitoral Gland Atrophy Degeneration Inflammation, Suppurative Ovary Angiectasis Atrophy Cyst Cyst Dermoid	45 (98%) (48) 40 (83%)	1 (2%) 43 (93%) 1 (2%) (47) 42 (89%)	1 (2%) 42 (91%) (46) 38 (83%) 21 (46%)	24 (96%) 1 (4%) (25) 23 (92%)	1 (2%) 43 (91%) (48) 43 (90%)	42 (91%) (47) 40 (85%)
Clitoral Gland Atrophy Degeneration Inflammation, Suppurative Ovary Angiectasis Atrophy Cyst Cyst Cyst Dermoid Hematocyst Infiltration Cellular, Lymphocyte	45 (98%) (48) 40 (83%)	1 (2%) 43 (93%) 1 (2%) (47) 42 (89%)	1 (2%) 42 (91%) (46) 38 (83%)	24 (96%) 1 (4%) (25) 23 (92%)	1 (2%) 43 (91%) (48) 43 (90%) 19 (40%)	42 (91%) (47) 40 (85%) 13 (28%)
Clitoral Gland Atrophy Degeneration Inflammation, Suppurative Ovary Angiectasis Atrophy Cyst Cyst Dermoid Hematocyst Infiltration Cellular, Lymphocyte Inflammation, Chronic Active Bilateral, Cyst Fat, Necrosis	45 (98%) (48) 40 (83%) 21 (44%)	1 (2%) 43 (93%) 1 (2%) (47) 42 (89%) 20 (43%)	1 (2%) 42 (91%) (46) 38 (83%) 21 (46%)	24 (96%) 1 (4%) (25) 23 (92%)	1 (2%) 43 (91%) (48) 43 (90%) 19 (40%)	42 (91%) (47) 40 (85%) 13 (28%) 1 (2%)
Clitoral Gland Atrophy Degeneration Inflammation, Suppurative Ovary Angiectasis Atrophy Cyst Cyst Dermoid Hematocyst Infiltration Cellular, Lymphocyte Inflammation, Chronic Active Bilateral, Cyst Fat, Necrosis Germinal Epithelium, Hyperplasia	45 (98%) (48) 40 (83%) 21 (44%) 1 (2%) 8 (17%)	1 (2%) 43 (93%) 1 (2%) (47) 42 (89%) 20 (43%)	1 (2%) 42 (91%) (46) 38 (83%) 21 (46%) 1 (2%)	24 (96%) 1 (4%) (25) 23 (92%) 8 (32%)	1 (2%) 43 (91%) (48) 43 (90%) 19 (40%) 1 (2%) 1 (2%)	42 (91%) (47) 40 (85%) 13 (28%) 1 (2%) 2 (4%)
Clitoral Gland Atrophy Degeneration Inflammation, Suppurative Ovary Angiectasis Atrophy Cyst Cyst Dermoid Hematocyst Infiltration Cellular, Lymphocyte Inflammation, Chronic Active Bilateral, Cyst Fat, Necrosis Germinal Epithelium, Hyperplasia Parenchymal Cell, Degeneration Uterus Angiectasis	45 (98%) (48) 40 (83%) 21 (44%)	1 (2%) 43 (93%) 1 (2%) (47) 42 (89%) 20 (43%)	1 (2%) 42 (91%) (46) 38 (83%) 21 (46%) 1 (2%)	24 (96%) 1 (4%) (25) 23 (92%) 8 (32%) 4 (16%)	1 (2%) 43 (91%) (48) 43 (90%) 19 (40%) 1 (2%) 1 (2%)	42 (91%) (47) 40 (85%) 13 (28%) 1 (2%) 2 (4%)
Clitoral Gland Atrophy Degeneration Inflammation, Suppurative Ovary Angiectasis Atrophy Cyst Cyst Dermoid Hematocyst Infiltration Cellular, Lymphocyte Inflammation, Chronic Active Bilateral, Cyst Fat, Necrosis Germinal Epithelium, Hyperplasia Parenchymal Cell, Degeneration Uterus	45 (98%) (48) 40 (83%) 21 (44%) 1 (2%) 8 (17%)	1 (2%) 43 (93%) 1 (2%) (47)  42 (89%) 20 (43%)  2 (4%)	1 (2%) 42 (91%) (46) 38 (83%) 21 (46%) 1 (2%) 5 (11%)	24 (96%) 1 (4%) (25) 23 (92%) 8 (32%)	1 (2%) 43 (91%)  (48)  43 (90%) 19 (40%)  1 (2%) 1 (2%) 2 (4%)	42 (91%) (47) 40 (85%) 13 (28%) 1 (2%) 2 (4%) 3 (6%)

TDMS No. 20311 - 02 Test Type: CHRONIC

Species/Strain: MICE/B6C3F1/NCTR

a - Number of animals examined microscopically at site and number of animals with lesion

 $\label{eq:AZT/Drug} \ Combinations \ Transplacental \ Carcinogenesis \ Study$ 

CAS Number: AIDSTHERAPEU

Date Report Requested: 06/29/2009 Time Report Requested: 16:30:20 First Dose M/F: NA / 07/10/03

Lab: NCTR

Species/Strain: MICE/B6C3F1/NCTR

TDMS No. 20311 - 02 Test Type: CHRONIC

C57BL/6N XC3H/HEN MTV-NCTR MICE FEMALE	AZTH/3TCH/NVPH/0	AZTM/3TCM/NVPM/0	AZTL/3TCL/NVPL/0	AZTH/3TCH/NFVH/0	AZTM/3TCM/NFVM/0	AZTL/3TCL/NFVL/
HEMATOPOIETIC SYSTEM						
Bone Marrow Hyperplasia Pigmentation	(48) 1 (2%)	(46) 1 (2%)	(46) 1 (2%)	(25) 1 (4%)	(47) 2 (4%)	(47) 3 (6%)
Lymph Node Cyst	(4)	(5)	(11)	(3)	(6)	(13)
Hemorrhage Hyperplasia, Lymphoid Axillary, Autolysis	1 (25%) 1 (25%)					
Axillary, Hyperplasia, Lymphoid Bronchial, Autolysis Iliac, Autolysis						1 (8%)
Lumbar, Autolysis Lumbar, Cyst					1 (17%)	
Lumbar, Fibrosis Lumbar, Hyperplasia, Lymphoid Lumbar, Infiltration Cellular, Plasma Cell Lumbar, Infiltration Cellular,						2 (15%) 1 (8%)
Polymorphonuclear Lumbar, Inflammation, Chronic Active Lumbar, Polyarteritis Mediastinal, Autolysis					1 (17%)	1 (8%)
Mediastinal, Hyperplasia, Lymphoid Mediastinal, Infiltration Cellular, Plasma Cell		1 (20%) 1 (20%)				
Pancreatic, Hyperplasia, Lymphoid Renal, Autolysis						1 (8%)
Renal, Hyperplasia, Lymphoid Renal, Infiltration Cellular, Plasma Cell Renal, Infiltration Cellular, Polymorphonuclear						2 (15%)
Sinus, Dilatation Lymph Node, Mandibular Autolysis	1 (25%) (47)	(47)	(47)	(25)	(48)	(48)
Erythrophagocytosis Hyperplasia, Lymphoid Infiltration Cellular, Plasma Cell Infiltration Cellular, Polymorphonuclear	18 (38%) 1 (2%)	18 (38%) 1 (2%)	11 (23%) 1 (2%)	6 (24%)	14 (29%)	13 (27%) 1 (2%)
Pigmentation Lymph Node, Mesenteric Angiectasis Autolysis	1 (2%) (47)	(46) 1 (2%)	(46)	(25)	(47)	(48)
Cyst Hematopoietic Cell Proliferation Hemorrhage		1 (2%)				

a - Number of animals examined microscopically at site and number of animals with lesion

 $\label{lem:azt/Drug} \ \ Combinations \ \ Transplacental \ \ Carcinogenesis \ \ Study$ 

CAS Number: AIDSTHERAPEU

Date Report Requested: 06/29/2009 Time Report Requested: 16:30:20 First Dose M/F: NA / 07/10/03

Lab: NCTR

C57BL/6N XC3H/HEN MTV-NCTR MICE FEMALE	AZTH/3TCH/NVPH/0	AZTM/3TCM/NVPM/0	AZTL/3TCL/NVPL/0	AZTH/3TCH/NFVH/0	AZTM/3TCM/NFVM/0	AZTL/3TCL/NFVL/
Hyperplasia						
Hyperplasia, Lymphoid Infiltration Cellular, Histiocyte	18 (38%)	21 (46%)	10 (22%)	11 (44%)	21 (45%) 2 (4%)	27 (56%)
Infiltration Cellular, Plasma Cell Infiltration Cellular, Polymorphonuclear Inflammation, Chronic Active Thrombosis	2 (4%)	1 (2%)			1 (2%)	4 (8%)
Sinus, Dilatation		2 (4%)				
Spleen	(48)	(47)	(47)	(25)	(48)	(50)
, Autolysis	( - /	,	( )	( - /	1 (2%)	()
Erythrophagocytosis						
Hematopoietic Cell Proliferation	9 (19%)	15 (32%)	10 (21%)	8 (32%)	9 (19%)	12 (24%)
Hemorrhage	20 (63%)	20 (649/)	OF (F20/)	4.4 (ECO()	1 (2%) 27 (56%)	22 (640/)
Hyperplasia, Lymphoid Necrosis	30 (63%)	30 (64%)	25 (53%)	14 (56%)	27 (56%) 1 (2%)	32 (64%)
Pigmentation					1 (270)	
Thrombosis		1 (2%)				
Thymus	(40)	(44)	(44)	(25)	(48)	(44)
Angiectasis	1 (3%)					
Atrophy	6 (15%)	11 (25%)	11 (25%)	7 (28%)	6 (13%)	18 (41%)
Autolysis	40 (050()	40 (220()	4 (00/)	4 (400/)	42 (270/)	0 (400/)
Hyperplasia, Lymphoid Mineralization	10 (25%)	10 (23%)	4 (9%)	4 (16%)	13 (27%)	8 (18%)
Fat, Necrosis						
NTEGUMENTARY SYSTEM						
Mammary Gland	(47)	(47)	(47)	(24)	(48)	(47)
Galactocele	(47)	(41)	(41)	(24)	(40)	(47)
Lactation						1 (2%)
Metaplasia, Squamous	1 (2%)					
Alveolus, Hyperplasia	2 (4%)	1 (2%)			3 (6%)	1 (2%)
Skin	(49)	(47)	(47)	(25)	(48)	(49)
Fibrosis	1 (2%)					4 (20/)
Infiltration Cellular, Lymphocyte Inflammation, Chronic Active	1 (2%)					1 (2%)
Ulcer	1 (2%)					
MUSCULOSKELETAL SYSTEM						
Bone, Femur	(49)	(48)	(48)	(26)	(49)	(50)
Fibro-Osseous Lesion		1 (2%)	2 (4%)	1 (4%)		
Skeletal Muscle	(1)	(2)	(0)	(0)	(0)	(0)

TDMS No. 20311 - 02 Test Type: CHRONIC

Species/Strain: MICE/B6C3F1/NCTR

a - Number of animals examined microscopically at site and number of animals with lesion

AZT/Drug Combinations Transplacental Carcinogenesis Study

CAS Number: AIDSTHERAPEU

Date Report Requested: 06/29/2009 Time Report Requested: 16:30:20 First Dose M/F: NA / 07/10/03

Lab: NCTR

TDMS No. 20311 - 02 Test Type: CHRONIC

C57BL/6N XC3H/HEN MTV-NCTR MICE FEMALE	AZTH/3TCH/NVPH/0	AZTM/3TCM/NVPM/0	AZTL/3TCL/NVPL/0	AZTH/3TCH/NFVH/0	AZTM/3TCM/NFVM/0	AZTL/3TCL/NFVL/
NERVOUS SYSTEM						
Brain, Brain Stem Compression Degeneration	(47) 2 (4%)	(46) 1 (2%) 1 (2%)	(46)	(25)	(48) 3 (6%)	(47) 2 (4%)
Hemorrhage Brain, Cerebellum	(47)	(46)	(46)	(25)	(48)	(47)
Hemorrhage Infiltration Cellular, Lymphocyte Vacuolization Cytoplasmic Meninges, Infiltration Cellular, Lymphocyte				1 (4%) 1 (4%)		1 (2%)
Ventricle, Dilatation Brain, Cerebrum Cyst Epithelial Inclusion	(47)	(46)	(46)	(25)	1 (2%) (48)	(47) 1 (2%)
Hemorrhage Mineralization	19 (40%)	16 (35%)	25 (54%)	5 (20%)	18 (38%)	1 (2%) 25 (53%)
Meninges, Infiltration Cellular, Lymphocyte Ventricle, Dilatation Peripheral Nerve Axon, Degeneration	(1) 1 (100%)	1 (2%) (1)	(0)	(0)	1 (2%) (0)	(0)
Spinal Cord Degeneration Inflammation, Chronic Active	(1)	(1) 1 (100%) 1 (100%)	(0)	(0)	(0)	(0)
Axon, Degeneration	1 (100%)	1 (10070)				
RESPIRATORY SYSTEM						
Lung Autolysis	(48) 1 (2%)	(47)	(46)	(25)	(47)	(50)
Congestion Crystals	1 (2%)	2 (4%)		2 (8%)	1 (2%) 1 (2%)	1 (2%)
Hemorrhage Infiltration Cellular, Histiocyte Infiltration Cellular, Lymphocyte	1 (2%) 13 (27%)	1 (2%) 3 (6%) 15 (32%)	1 (2%) 8 (17%)	2 (8%) 4 (16%)	4 (9%) 9 (19%)	1 (2%) 14 (28%)
Inflammation, Chronic Inflammation, Chronic Active		1 (2%)	1 (2%)			1 (2%)
Metaplasia, Osseous Alveolar Epithelium, Hyperplasia	1 (2%)	2 (4%)	2 (4%)	1 (4%)	1 (2%)	1 (2%)
Bronchiole, Hyperplasia Nose Inflammation, Suppurative	(49)	(47)	1 (2%) (48) 1 (2%)	(26)	(47)	(48)
Posterior To Upper Incisor, Dysplasia		1 (2%)	, ,			

a - Number of animals examined microscopically at site and number of animals with lesion

 $\label{eq:AZT/Drug} \ Combinations \ Transplacental \ Carcinogenesis \ Study$ 

CAS Number: AIDSTHERAPEU

Date Report Requested: 06/29/2009 Time Report Requested: 16:30:20 First Dose M/F: NA / 07/10/03

Lab: NCTR

C57BL/6N XC3H/HEN MTV-NCTR MICE FEMALE	AZTH/3TCH/NVPH/0	AZTM/3TCM/NVPM/0	AZTL/3TCL/NVPL/0	AZTH/3TCH/NFVH/0	AZTM/3TCM/NFVM/0	AZTL/3TCL/NFVL/
SPECIAL SENSES SYSTEM						
Eye Cataract Degeneration Inflammation, Chronic Active	(45) 1 (2%)	(45) 2 (4%)	(45) 1 (2%)	(25) 1 (4%)	(47) 1 (2%) 1 (2%) 1 (2%)	(45) 1 (2%)
Metaplasia, Squamous Bilateral, Cataract Cornea, Inflammation, Chronic Active	1 (2%)	1 (2%) 1 (2%)	1 (2%) 2 (4%)	1 (4%) 1 (4%)	1 (2%)	
Cornea, Necrosis Cornea, Ulcer Retina, Degeneration	1 (2%)	1 (2%)	1 (2%)			
Harderian Gland Cyst	(46)	(45)	(45)	(25)	(46)	(46) 1 (2%)
Infiltration Cellular, Lymphocyte Inflammation, Chronic Inflammation, Chronic Active	5 (11%)	5 (11%) 1 (2%)	5 (11%)	2 (8%)	4 (9%)	4 (9%) 1 (2%) 1 (2%)
Acinus, Degeneration Acinus, Hyperplasia Epithelium, Hyperplasia	1 (2%)			1 (4%)		2 (4%)
JRINARY SYSTEM						
Kidney Amyloid Deposition Hemorrhage	(47)	(47)	(48) 1 (2%)	(25)	(47)	(47)
Hyaline Droplet Hydronephrosis Hyperplasia, Lymphoid	1 (2%)			1 (4%)	1 (2%)	2 (4%)
Infiltration Cellular, Lymphocyte Inflammation, Chronic Active	11 (23%)	15 (32%)	15 (31%)	5 (20%)	15 (32%) 1 (2%)	7 (15%)
Metaplasia, Osseous Nephropathy Polyarteritis Adventitia, Inflammation, Chronic Active	30 (64%)	22 (47%)	1 (2%) 19 (40%)	12 (48%)	23 (49%)	1 (2%) 30 (64%) 1 (2%)
Adventitia, Fat, Necrosis Urinary Bladder	(46)	(46)	(47)	(25)	(47)	(47)
Edema Infiltration Cellular, Lymphocyte Inflammation, Chronic Active Polyarteritis Lumen, Dilatation	21 (46%)	25 (54%)	24 (51%)	10 (40%)	23 (49%)	19 (40%) 1 (2%)

TDMS No. 20311 - 02 Test Type: CHRONIC

Species/Strain: MICE/B6C3F1/NCTR

a - Number of animals examined microscopically at site and number of animals with lesion

# TDMS No. 20311 - 02 Test Type: CHRONIC

Route: IN-UTERO

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

 $\label{lem:azt/Drug} \ \ Combinations \ \ Transplacental \ \ Carcinogenesis \ \ Study$ 

CAS Number: AIDSTHERAPEU

Date Report Requested: 06/29/2009 Time Report Requested: 16:30:20 First Dose M/F: NA / 07/10/03

Lab: NCTR

**Species/Strain:** MICE/B6C3F1/NCTR

C57BL/6N XC3H/HEN MTV-NCTR MICE AZTH/3TCH/NVPH/0 AZTM/3TCM/NVPM/0 AZTL/3TCL/NVPL/0 AZTH/3TCH/NFVH/0 AZTM/3TCM/NFVM/0 AZTL/3TCL/NFVL/0 FEMALE

AZT/Drug Combinations Transplacental Carcinogenesis Study

CAS Number: AIDSTHERAPEU

Date Report Requested: 06/29/2009 Time Report Requested: 16:30:20 First Dose M/F: NA / 07/10/03

Lab: NCTR

C57BL/6N XC3H/HEN MTV-NCTR MICE FEMALE	SOLVENT to 0		
Disposition Summary			
Animals Initially in Study Early Deaths	64		
Moribund Sacrifice	7		
Natural Death	3		
Survivors			
Moribund Sacrifice	6		
Natural Death	1		
Terminal Sacrifice	45		
Harvest	2		
Animals Examined Microscopically	64		
ALIMENTARY SYSTEM			
Esophagus	(62)		
Gallbladder	(60)		
Cyst	, ,		
Degeneration, Hyaline Infiltration Cellular, Lymphocyte Inflammation, Chronic			
Intestine Large, Cecum	(60)		
Hyperplasia, Lymphoid	(00)		
Serosa, Hyperplasia	1 (2%)		
Intestine Large, Colon	(60)		
Intestine Large, Rectum	(60)		
Hyperplasia, Lymphoid			
Intestine Small, Duodenum	(60)		
Diverticulum			
Intestine Small, Ileum	(60)		
Hyperplasia, Lymphoid	4 (00()		
Inflammation, Chronic Active	1 (2%)		
Intestine Small, Jejunum	(60)		
Hyperplasia, Lymphoid Epithelium, Hyperplasia	1 (2%)		
Liver	(61)		
Angiectasis	(01)		
Autolysis			
Basophilic Focus	2 (3%)		
Basophilic Focus, Multiple	_ (-,-,		
Clear Cell Focus			

1 (2%)

TDMS No. 20311 - 02 Test Type: CHRONIC

Species/Strain: MICE/B6C3F1/NCTR

Clear Cell Focus Congestion Cyst

a - Number of animals examined microscopically at site and number of animals with lesion

AZT/Drug Combinations Transplacental Carcinogenesis Study

CAS Number: AIDSTHERAPEU

Date Report Requested: 06/29/2009 Time Report Requested: 16:30:20 First Dose M/F: NA / 07/10/03

Lab: NCTR

C57BL/6N XC3H/HEN MTV-NCTR MICE FEMALE	SOLVENT to 0
Cyct Multilocular	
Cyst Multilocular Deformity	
Eosinophilic Focus	3 (5%)
Eosinophilic Focus, Multiple	3 (370)
Fatty Change	
Hematocyst	
Hematopoietic Cell Proliferation	2 (3%)
Hemorrhage	2 (070)
Hepatodiaphragmatic Nodule	
Infiltration Cellular, Histiocyte	1 (2%)
Infiltration Cellular, Lymphocyte	18 (30%)
Inflammation, Chronic Active	5 (8%)
Mineralization	1 (2%)
Mixed Cell Focus	1 (2%)
Necrosis	3 (5%)
Tension Lipidosis	7 (11%)
Vacuolization Cytoplasmic	32 (52%)
Mesentery	(8)
Cyst	( )
Hematocyst	
Hemorrhage	
Infiltration Cellular, Lymphocyte	
Fat, Necrosis	8 (100%)
Pancreas	(62)
Cyst	1 (2%)
Cytoplasmic Alteration	
Edema	
Infiltration Cellular, Lymphocyte	23 (37%)
Inflammation, Chronic Active	
Mineralization	
Necrosis	
Acinus, Degeneration	2 (3%)
Duct, Dilatation	
Fat, Necrosis	(00)
Salivary Glands	(62)
Infiltration Cellular, Lymphocyte	47 (76%)
Polyarteritis	
Acinus, Degeneration	(00)
Stomach, Forestomach	(62)
Hyperkeratosis	
Hyperplasia	
Inflammation, Chronic Active	
Keratin Cyst Ulcer	1 (2%)
Epithelium, Hyperplasia	2 (3%)
	` ,
Stomach, Glandular	(60)

TDMS No. 20311 - 02 Test Type: CHRONIC

Species/Strain: MICE/B6C3F1/NCTR

a - Number of animals examined microscopically at site and number of animals with lesion

AZT/Drug Combinations Transplacental Carcinogenesis Study

**CAS Number:** AIDSTHERAPEU

Date Report Requested: 06/29/2009 Time Report Requested: 16:30:20 First Dose M/F: NA / 07/10/03

Lab: NCTR

C57BL/6N XC3H/HEN MTV-NCTR MICE FEMALE	SOLVENT to 0		
Degeneration, Hyaline Infiltration Cellular, Lymphocyte Inflammation, Chronic Active Mineralization Epithelium, Hyperplasia	1 (2%)		
CARDIOVASCULAR SYSTEM			
Blood Vessel Heart Cardiomyopathy Inflammation, Suppurative Inflammation, Chronic Active Mineralization	(62) (63) 1 (2%)		
Necrosis Polyarteritis			
ENDOCRINE SYSTEM			
Adrenal Cortex Accessory Adrenal Cortical Nodule Angiectasis Cyst	(61) 6 (10%)		
Hypertrophy Vacuolization Cytoplasmic Subcapsular, Hyperplasia Adrenal Medulla Hyperplasia	1 (2%) 3 (5%) 60 (98%) (60)		
Islets, Pancreatic Hyperplasia Infiltration Cellular, Lymphocyte Parathyroid Gland	(62) 1 (2%) 1 (2%) (54)		
Cyst Hyperplasia Hypertrophy Infiltration Cellular, Lymphocyte	1 (2%)		
Pituitary Gland Hemorrhage Pars Distalis, Angiectasis Pars Distalis, Cyst	(60) 1 (2%) 2 (3%)		
Pars Distalis, Hyperplasia Rathke's Cleft, Dilatation Thyroid Gland Cyst	8 (13%) (59)		

TDMS No. 20311 - 02 Test Type: CHRONIC

Species/Strain: MICE/B6C3F1/NCTR

a - Number of animals examined microscopically at site and number of animals with lesion

AZT/Drug Combinations Transplacental Carcinogenesis Study

CAS Number: AIDSTHERAPEU

Date Report Requested: 06/29/2009 Time Report Requested: 16:30:20 First Dose M/F: NA / 07/10/03

Lab: NCTR

C57BL/6N XC3H/HEN MTV-NCTR MICE FEMALE	SOLVENT to 0	
Ectopic Thymus Infiltration Cellular, Lymphocyte Inflammation, Chronic Active Polyarteritis	1 (2%) 2 (3%)	
C-cell, Hyperplasia Follicle, Degeneration Follicular Cell, Hyperplasia	9 (15%)	
Follicular Cell, Hypertrophy	2 (3%)	
GENERAL BODY SYSTEM		
Tissue NOS Hemorrhage Infiltration Cellular, Lymphocyte Abdominal, Fibrosis	(3)	
Abdominal, Inflammation, Chronic Active Abdominal, Keratin Cyst Fat, Necrosis	1 (33%)	
GENITAL SYSTEM		
Clitoral Gland Atrophy	(60)	
Degeneration Inflammation, Suppurative	55 (92%)	
Ovary Angiectasis	(60)	
Atrophy Cyst Cyst Dermoid Hematocyst	57 (95%) 22 (37%)	
Infiltration Cellular, Lymphocyte Inflammation, Chronic Active Bilateral, Cyst Fat, Necrosis Germinal Epithelium, Hyperplasia	3 (5%)	
Parenchymal Cell, Degeneration Uterus Angiectasis Autolysis	(62)	
Hydrometra Thrombosis	9 (15%)	
Endometrium, Hyperplasia, Cystic	52 (84%)	

TDMS No. 20311 - 02 Test Type: CHRONIC

Species/Strain: MICE/B6C3F1/NCTR

a - Number of animals examined microscopically at site and number of animals with lesion

AZT/Drug Combinations Transplacental Carcinogenesis Study

CAS Number: AIDSTHERAPEU

Date Report Requested: 06/29/2009 Time Report Requested: 16:30:20 First Dose M/F: NA / 07/10/03

Lab: NCTR

#### C57BL/6N XC3H/HEN MTV-NCTR MICE

**FEMALE** 

Route: IN-UTERO

TDMS No. 20311 - 02 Test Type: CHRONIC

SOLVENT to 0

#### HEMATOPOIETIC SYSTEM

Species/Strain: MICE/B6C3F1/NCTR

MATOPOIETIC SYSTEM	
Bone Marrow Hyperplasia Pigmentation	(61) 2 (3%)
Lymph Node	(15)
Cyst Hemorrhage	1 (7%)
Hyperplasia, Lymphoid Axillary, Autolysis	1 (7%)
Axillary, Hyperplasia, Lymphoid Bronchial, Autolysis	1 (7%)
Iliac, Autolysis Lumbar, Autolysis Lumbar, Cyst	1 (7%) 1 (7%)
Lumbar, Fibrosis Lumbar, Hyperplasia, Lymphoid	5 (33%)
Lumbar, Infiltration Cellular, Plasma Cell Lumbar, Infiltration Cellular,	1 (7%) 2 (13%)
Polymorphonuclear Lumbar, Inflammation, Chronic Active	
Lumbar, Polyarteritis Mediastinal, Autolysis	1 (7%)
Mediastinal, Hyperplasia, Lymphoid Mediastinal, Infiltration Cellular, Plasma Cell Pancreatic, Hyperplasia, Lymphoid	1 (7%)
Renal, Autolysis Renal, Hyperplasia, Lymphoid	1 (7%) 1 (7%)
Renal, Infiltration Cellular, Plasma Cell	, ,
Renal, Infiltration Cellular, Polymorphonuclear Sinus, Dilatation	1 (7%) 1 (7%)
Lymph Node, Mandibular Autolysis Erythrophagocytosis	(61) 1 (2%) 1 (2%)
Hyperplasia, Lymphoid Infiltration Cellular, Plasma Cell	16 (26%) 1 (2%)
Infiltration Cellular, Polymorphonuclear	1 (2%)
Pigmentation Lymph Node, Mesenteric	(60)
Angiectasis Autolysis	1 (2%)
Cyst Hematopoietic Cell Proliferation Hemorrhage	
Hemomaye	

a - Number of animals examined microscopically at site and number of animals with lesion

AZT/Drug Combinations Transplacental Carcinogenesis Study

CAS Number: AIDSTHERAPEU

Date Report Requested: 06/29/2009 Time Report Requested: 16:30:20 First Dose M/F: NA / 07/10/03

Lab: NCTR

C57BL/6N XC3H/HEN MTV-NCTR MICE FEMALE	SOLVENT to 0
I haramataria	
Hyperplasia	00 (000)
Hyperplasia, Lymphoid	20 (33%)
Infiltration Cellular, Histiocyte	1 (2%)
Infiltration Cellular, Plasma Cell	1 (2%)
Infiltration Cellular, Polymorphonuclear	1 (2%)
Inflammation, Chronic Active	
Thrombosis	1 (2%)
Sinus, Dilatation	(22)
Spleen	(62)
Autolysis	1 (2%)
Erythrophagocytosis	1 (2%)
Hematopoietic Cell Proliferation	14 (23%)
Hemorrhage	00 (500()
Hyperplasia, Lymphoid	32 (52%)
Necrosis	
Pigmentation	
Thrombosis	(55)
Thymus	(55)
Angiectasis	40 (040/)
Atrophy	13 (24%)
Autolysis	40 (000)
Hyperplasia, Lymphoid	12 (22%)
Mineralization	
Fat, Necrosis	
INTEGUMENTARY SYSTEM	
Mammary Gland	(63)
Galactocele	(00)
Lactation	2 (3%)
Metaplasia, Squamous	_ (
Alveolus, Hyperplasia	2 (3%)
Skin	(63)
Fibrosis	(00)
Infiltration Cellular, Lymphocyte	
Inflammation, Chronic Active	
Ulcer	
MUSCULOSKELETAL SYSTEM	
Bone, Femur	(64)
Fibro-Osseous Lesion	
Skeletal Muscle	(1)

TDMS No. 20311 - 02 Test Type: CHRONIC

Species/Strain: MICE/B6C3F1/NCTR

a - Number of animals examined microscopically at site and number of animals with lesion

AZT/Drug Combinations Transplacental Carcinogenesis Study

CAS Number: AIDSTHERAPEU

Date Report Requested: 06/29/2009 Time Report Requested: 16:30:20 First Dose M/F: NA / 07/10/03

Lab: NCTR

C57BL/6N XC3H/HEN MTV-NCTR MICE FEMALE	SOLVENT to 0	
NERVOUS SYSTEM		
Brain, Brain Stem	(61)	
Compression	1 (2%)	
Degeneration		
Hemorrhage	1 (2%)	
Brain, Cerebellum	(62)	
Hemorrhage		
Infiltration Cellular, Lymphocyte		
Vacuolization Cytoplasmic		
Meninges, Infiltration Cellular, Lymphocyte		
Ventricle, Dilatation	(00)	
Brain, Cerebrum Cyst Epithelial Inclusion	(62)	
Hemorrhage		
Mineralization	41 (66%)	
Meninges, Infiltration Cellular, Lymphocyte	41 (0070)	
Ventricle, Dilatation		
Peripheral Nerve	(1)	
Axon, Degeneration	( )	
Spinal Cord	(1)	
Degeneration	• •	
Inflammation, Chronic Active		
Axon, Degeneration		
RESPIRATORY SYSTEM		
Lung	(62)	
Autolysis		
Congestion		
Crystals	5 (8%)	
Hemorrhage	1 (2%)	
Infiltration Cellular, Histiocyte	8 (13%)	
Infiltration Cellular, Lymphocyte Inflammation, Chronic	19 (31%)	
Inflammation, Chronic Inflammation, Chronic Active		
Metaplasia, Osseous	1 (2%)	
Alveolar Epithelium, Hyperplasia	3 (5%)	
Bronchiole, Hyperplasia	3 (370)	
Nose	(62)	
Inflammation, Suppurative	1 (2%)	
Posterior To Upper Incisor, Dysplasia	· · · /	
• • • • •		

TDMS No. 20311 - 02 Test Type: CHRONIC

Species/Strain: MICE/B6C3F1/NCTR

a - Number of animals examined microscopically at site and number of animals with lesion

AZT/Drug Combinations Transplacental Carcinogenesis Study

CAS Number: AIDSTHERAPEU

Date Report Requested: 06/29/2009 Time Report Requested: 16:30:20 First Dose M/F: NA / 07/10/03

Lab: NCTR

C57BL/6N XC3H/HEN MTV-NCTR MICE FEMALE	SOLVENT to 0	
SPECIAL SENSES SYSTEM		
Eye Cataract Degeneration Inflammation, Chronic Active Metaplasia, Squamous Bilateral, Cataract	(59)	
Cornea, Inflammation, Chronic Active Cornea, Necrosis Cornea, Ulcer Retina, Degeneration	1 (2%)	
Harderian Gland	(60)	
Cyst Infiltration Cellular, Lymphocyte Inflammation, Chronic Inflammation, Chronic Active Acinus, Degeneration Acinus, Hyperplasia Epithelium, Hyperplasia	7 (12%)	
URINARY SYSTEM		
Kidney Amyloid Deposition Hemorrhage Hyaline Droplet Hydronephrosis Hyperplasia, Lymphoid	(62) 1 (2%)	
Infiltration Cellular, Lymphocyte Inflammation, Chronic Active	17 (27%)	
Metaplasia, Osseous Nephropathy Polyarteritis Adventitia, Inflammation, Chronic Active Adventitia, Fat, Necrosis	2 (3%) 31 (50%)	
Urinary Bladder Edema	(60)	
Infiltration Cellular, Lymphocyte Inflammation, Chronic Active Polyarteritis	20 (33%)	
Lumen, Dilatation	1 (2%)	

TDMS No. 20311 - 02 Test Type: CHRONIC

Species/Strain: MICE/B6C3F1/NCTR

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 20311 - 02 Test Type: CHRONIC P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

AZT/Drug Combinations Transplacental Carcinogenesis Study

**CAS Number:** AIDSTHERAPEU

Date Report Requested: 06/29/2009 Time Report Requested: 16:30:20 First Dose M/F: NA / 07/10/03

Lab: NCTR

C57BL/6N XC3H/HEN MTV-NCTR MICE

Species/Strain: MICE/B6C3F1/NCTR

**FEMALE** 

Route: IN-UTERO

SOLVENT to 0

\*\*\* END OF REPORT \*\*\*